Summary of key vaccine therapy clinical trials for treatment of lymphoma

Study	Lymphoma subtype	Vaccine type	Induction therapy	Patients (n)	Immune response	Efficacy
Levy et al.¹¹⁴	Untreated FL	Protein-based; Id-KLH + GM-CSF vs. KLH + GM-CSF	CVP	287	Anti-Id humoral responses in 41% of treated patients.	Median PFS 19.1 months (experimental) vs. 23.3 months (control)
Freedman et al.¹¹⁵	Untreated FL	Protein-based; Id-KLH + GM-CSF vs. placebo + GM-CSF	Rituximab	349	N/A	Median TTP 9 months (experimental) vs. 12.6 months (control) (HR = 1.384; P = 0.019)
Schuster et al.¹¹⁶	Untreated FL	Protein-based; Id-KLH + GM-CSF vs. KLH + GM-CSF	PACE	177	IgM isotype vaccines compared to IgG isotypes improves survival (52.9 vs.28.7 months, P = 0.001)	Median DFS 44.2 months (experimental), vs. 30.6 months (control) (HR, 0.62; P = 0.047)
Di NiCola et al.¹¹⁹	R/R indolent B-cell NHL	DC loaded killed autologous tumor cell vaccine	N/A	18	Humoral responses against lymphoma antigens. Decrease in regulatory T-cells and increase in cytotoxic NK cells	ORR 33%, with 3 CRs
Brody et al.¹²⁶	R/R indolent B-cell NHL	In situ vaccination with CpG DNA + XRT	N/A	15	Vaccination resulted in the development of tumor-reactive memory CD8+ T-cells	ORR 27%, with 1 CR
Kim et al.¹²⁷	R/R CTCL	In situ vaccination with CpG DNA + XRT	N/A	15	Immunized sites appeared to demonstrate a reduction in infiltration of regulatory T-cells	5 clinical responses noted